Satellos Bioscience

Satellos

This company develops small molecule therapeutics to restore muscle regeneration for patients with Duchenne muscular dystrophy and other degenerative muscle diseases.

Edgewise Therapeutics

This biopharmaceutical company develops small molecule therapies for patients with serious cardiovascular diseases and musculoskeletal conditions like Duchenne and Becker muscular dystrophy.

MyoGene Bio

This company develops gene-editing therapies to treat Duchenne muscular dystrophy and other muscle-wasting diseases for patients worldwide.

MyoGene Bio

This company develops gene-editing therapies to treat patients with Duchenne muscular dystrophy by restoring production of the dystrophin protein.

MyoPax

This company develops muscle regeneration cell and gene therapies for patients with congenital malformations, trauma, hereditary dystrophies and muscle wasting disorders.

NMD Pharma

This company develops small molecule therapies for patients suffering from severe neuromuscular disorders to restore skeletal muscle function.

Edgewise

This biopharmaceutical company develops oral small molecule therapies to treat patients with rare skeletal and cardiac muscle diseases.

Augustine Therapeutics

This company develops small molecule inhibitors to treat patients with neuromuscular, neurodegenerative and cardio-metabolic diseases.